Navigation Links
ClinStar to Be Featured on Business Day TV With Terry Bradshaw
Date:12/8/2011

SAN FRANCISCO, Dec. 8, 2011 /PRNewswire/ -- ClinStar, LLC, an established CRO providing clinical research services in the emerging markets of Russia and Eastern Europe to the biopharmaceutical industry, announced today that it is being featured in a Medical Minutes series by Business Day TV hosted by Terry Bradshaw. 

According to the episode, it takes approximately 10 to 15 years and over one billion dollars to launch a new drug, and even then, only one in five products generate enough revenue to break-even. To speed up the process, biopharmaceutical companies utilize the services of Contract Research Organizations (CROs) to conduct the clinical research phase in patients. However, with qualified and interested patients becoming more difficult to find in the West, the industry is turning to CROs like ClinStar that geographically specialize in emerging markets. 

"More and more clinical research is being conducted outside the traditional markets of North America and Western Europe," says David Passov, President and CEO of ClinStar. "This is not necessarily driven only by somewhat lower cost but rather by the ability to significantly speed up drug development by accessing a global population of 7 billion people."

Specializing in the emerging markets of Russia, Ukraine, Belarus and the Baltic States, ClinStar leverages the region's combined population of over 200 million and the support of physicians and government regulatory bodies to enjoy recruitment rates up to 20 times faster than in the West.

"By conducting clinical trials in emerging markets, biopharmaceutical organizations are able to reduce the time to develop a drug," says Mr. Passov. "This not only translates into cost savings for the biopharmaceutical industry but results in faster access to better medicines for us all." 

View the full-length version of ClinStar featured on Business Day TV

Contact:
Heather Newbold
919-354-3573 ext. 276
heather.newbold@clinstar.com

About ClinStar, LLC
ClinStar is one of the most prominent CROs in the emerging markets of Eastern Europe and the Baltics with more than 10 years of expertise in Phase I-IV clinical studies in multiple therapeutic areas. Headquartered in San Francisco, California, ClinStar manages studies from its offices in Russia, Ukraine and Belarus, with total staff of over 260 people. Its portfolio contains over 130 clinical trials conducted for US and European pharmaceutical and biotechnology companies. More information is available at www.clinstar.com.


'/>"/>
SOURCE ClinStar, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ClinStar to Present on Clinical Trial Recruitment in the Emerging Regions of Russia and Eastern Europe
2. ClinStar to Present on Russias Performance as an Emerging Market in Global Clinical Trials
3. ClinStar to Present on Conducting Clinical Trials in Russia
4. ClinStar, LLC Establishes New Office on the US East Coast
5. Diplomat Specialty Pharmacy Recipient of MichBio Good to Great Award; Also Featured in Pure Michigan Video Exemplifying Flints Resurgence and Michigans Future
6. PLC Systems RenalGuard® to be Featured in Chronic Kidney Disease and Contrast Nephropathy Session at TCT 2011
7. Groundbreaking Approach to Predicting Cancer Patients Response to Treatment Featured in Science Magazine
8. Intellect Neurosciences CEO to be Featured on Wall Street Reporter
9. Additional Analysis from Two-Year Sequel Study of QNEXA Featured at The 2011 Annual Scientific Meeting of The Obesity Society
10. Medical Care Technologies Inc. to be Featured Guest on Business Radio Show Your Monies Worth
11. Sanovas CEO Larry Gerrans Featured Speaker at AdvaMed 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... MINNEAPOLIS , Feb. 10, 2016 Urologix, ... for the treatment of Benign Prostatic Hyperplasia (BPH), announces ... Ash Keswani , a medical device industry veteran ... of the Limited Liability Company.  ... and service lines, Cooled ThermoTherapy™ and Prostiva® RF Therapy, ...
(Date:2/10/2016)... , Feb. 10, 2016  Rich Pharmaceuticals, Inc. (OTC ... a 1-for-100 reverse split of its issued and outstanding ... trading on Thursday, February 11, 2016. The Company,s common ... CUSIP number 76303T308 and temporary ticker symbol "RCHAD". After ... under the ticker symbol (RCHA).  --> ...
(Date:2/10/2016)... -- Oxis International Inc. (OTC/QB: OXIS) announced today that the ... "clinical trial triumph" after one of the first patients ... Daniel Vallera , a research scientist ... --> Daniel Vallera , a research scientist ... --> An article on the University of ...
Breaking Medicine Technology:
(Date:2/10/2016)... St. Louis, Missouri (PRWEB) , ... February 10, ... ... 11-14, 2016, in San Diego, will bring together more than 200 of the ... in healthcare for the future. , “The true benefit of the Forum is ...
(Date:2/10/2016)... ... ... Gout is like no other joint pain. It strikes suddenly, like flicking on ... redness. It is triggered by the crystallization of uric acid within the joints. It ... to the February 2016 issue of Harvard Men's Health Watch. , The large joint ...
(Date:2/10/2016)... ... ... Armune BioScience signed a definitive agreement with ARCpoint Labs ... country. Launched in April of 2015, Apifiny is the only cancer specific, non-PSA blood ... exceeded 3,000 tests in 2015. Primary care physicians and urologists have utilized Apifiny to ...
(Date:2/10/2016)... ... February 10, 2016 , ... Pediatric ... in their patients. Research shows that the Goal Attainment Scale (GAS) captures 20% ... this challenge and learn more about the Goal Attainment Scale, Education Resources Inc. ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... the Ohio Safety Congress and Expo event March 9-11, 2016. Hosted by Ohio's ... Convention Center. , As the longest running and largest worker's compensation event ...
Breaking Medicine News(10 mins):